Four years after China established a pilot program enabling drug license holders to use third parties to manufacture their products, the National Medical Products Administration in August launched a database to allow drug makers and the public to more easily access information on pharmaceutical products that are part of the program. The new database houses details including pharmaceutical production, pharmacology and generic quality consistency of 156 Marketing Authorization Holder products.
